Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

NCT03744390 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT03744390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03744390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II Multicenter Study of IDH2 (AG-221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 2, 2019
Completion date
December 18, 2026
Enrollment
68 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia acute myeloid, myelodysplastic syndromes